Nasus Pharma Ltd. (AMEX: NSRX) Stock Competitors & Peer Comparison
See NSRX's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NSRX and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NSRX | $3.23 | -2.71% | 27.8M | -4.49 | -$0.72 | N/A |
| RPRX | $56.57 | -2.09% | 25.1B | 10.78 | $5.25 | +1.60% |
| CORT | $117.80 | -2.80% | 12.7B | 336.57 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $78.53 | -0.90% | 6B | 80.96 | $0.97 | N/A |
| LQDA | $26.81 | -3.11% | 2.4B | 19.57 | $1.37 | N/A |
| PBH | $48.53 | -0.97% | 2.3B | 10.98 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $15.71 | -1.94% | 945M | -6.23 | -$2.52 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
NSRX vs RPRX Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, RPRX has a market cap of 25.1B. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while RPRX trades at $56.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas RPRX's P/E ratio is 10.78. In terms of profitability, NSRX's ROE is -1.59%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, NSRX is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
NSRX vs CORT Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, CORT has a market cap of 12.7B. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while CORT trades at $117.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas CORT's P/E ratio is 336.57. In terms of profitability, NSRX's ROE is -1.59%, compared to CORT's ROE of +0.08%. Regarding short-term risk, NSRX is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
NSRX vs WBA Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas WBA's P/E ratio is -1.64. In terms of profitability, NSRX's ROE is -1.59%, compared to WBA's ROE of -0.57%. Regarding short-term risk, NSRX is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
NSRX vs KNSA Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while KNSA trades at $78.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas KNSA's P/E ratio is 80.96. In terms of profitability, NSRX's ROE is -1.59%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, NSRX is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
NSRX vs LQDA Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, LQDA has a market cap of 2.4B. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while LQDA trades at $26.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas LQDA's P/E ratio is 19.57. In terms of profitability, NSRX's ROE is -1.59%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, NSRX is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
NSRX vs PBH Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while PBH trades at $48.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas PBH's P/E ratio is 10.98. In terms of profitability, NSRX's ROE is -1.59%, compared to PBH's ROE of +0.09%. Regarding short-term risk, NSRX is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
NSRX vs HROWL Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas HROWL's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, NSRX is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
NSRX vs HROWM Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas HROWM's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, NSRX is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
NSRX vs LTGO Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, LTGO has a market cap of 945M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while LTGO trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas LTGO's P/E ratio is -6.23. In terms of profitability, NSRX's ROE is -1.59%, compared to LTGO's ROE of N/A. Regarding short-term risk, NSRX is more volatile compared to LTGO. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
NSRX vs HELP Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, HELP has a market cap of 650.8M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while HELP trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas HELP's P/E ratio is -2.52. In terms of profitability, NSRX's ROE is -1.59%, compared to HELP's ROE of -0.71%. Regarding short-term risk, NSRX is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
NSRX vs SVA Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas SVA's P/E ratio is -5.68. In terms of profitability, NSRX's ROE is -1.59%, compared to SVA's ROE of -0.01%. Regarding short-term risk, NSRX is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
NSRX vs CUVL Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, CUVL has a market cap of 275.6M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while CUVL trades at $5.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas CUVL's P/E ratio is 11.79. In terms of profitability, NSRX's ROE is -1.59%, compared to CUVL's ROE of N/A. Regarding short-term risk, NSRX is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CUVL's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
NSRX vs CELG-RI Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, CELG-RI has a market cap of 241M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to CELG-RI's ROE of +0.47%. Regarding short-term risk, NSRX is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
NSRX vs HITI Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while HITI trades at $2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas HITI's P/E ratio is -9.53. In terms of profitability, NSRX's ROE is -1.59%, compared to HITI's ROE of -0.36%. Regarding short-term risk, NSRX is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check HITI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
NSRX vs ETRA Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, ETRA has a market cap of 182.6M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while ETRA trades at $8.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas ETRA's P/E ratio is -3.25. In terms of profitability, NSRX's ROE is -1.59%, compared to ETRA's ROE of N/A. Regarding short-term risk, NSRX is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check ETRA's competition here
TRex Bio Inc. (NASDAQ: TRXB)
NSRX vs TRXB Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, TRXB has a market cap of 113.3M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while TRXB trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas TRXB's P/E ratio is -5.51. In terms of profitability, NSRX's ROE is -1.59%, compared to TRXB's ROE of N/A. Regarding short-term risk, NSRX is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check TRXB's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
NSRX vs CTOR Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, CTOR has a market cap of 71.6M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while CTOR trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas CTOR's P/E ratio is -1.64. In terms of profitability, NSRX's ROE is -1.59%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, NSRX is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
NSRX vs ATLN Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas ATLN's P/E ratio is -0.68. In terms of profitability, NSRX's ROE is -1.59%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, NSRX is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check ATLN's competition here
Retension Pharmaceuticals Inc. (NASDAQ: RTSN)
NSRX vs RTSN Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, RTSN has a market cap of 44.7M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while RTSN trades at $11.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas RTSN's P/E ratio is -4.57. In terms of profitability, NSRX's ROE is -1.59%, compared to RTSN's ROE of N/A. Regarding short-term risk, NSRX is less volatile compared to RTSN. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check RTSN's competition here
Rite Aid Corporation (NYSE: RAD)
NSRX vs RAD Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas RAD's P/E ratio is -0.05. In terms of profitability, NSRX's ROE is -1.59%, compared to RAD's ROE of +2.76%. Regarding short-term risk, NSRX is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
NSRX vs GLTO Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas GLTO's P/E ratio is -1.78. In terms of profitability, NSRX's ROE is -1.59%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, NSRX is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check GLTO's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
NSRX vs SCYX Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, SCYX has a market cap of 25.1M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while SCYX trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas SCYX's P/E ratio is -1.17. In terms of profitability, NSRX's ROE is -1.59%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, NSRX is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
NSRX vs COSM Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, COSM has a market cap of 20.8M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while COSM trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas COSM's P/E ratio is -0.52. In terms of profitability, NSRX's ROE is -1.59%, compared to COSM's ROE of -1.19%. Regarding short-term risk, NSRX is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check COSM's competition here
Cerenome, Inc. (NASDAQ: CNSY)
NSRX vs CNSY Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, CNSY has a market cap of 12M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while CNSY trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas CNSY's P/E ratio is -0.41. In terms of profitability, NSRX's ROE is -1.59%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, NSRX is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
NSRX vs BFRI Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, BFRI has a market cap of 11.4M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while BFRI trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas BFRI's P/E ratio is -1.62. In terms of profitability, NSRX's ROE is -1.59%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, NSRX is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
NSRX vs CJJD Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas CJJD's P/E ratio is -0.46. In terms of profitability, NSRX's ROE is -1.59%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, NSRX is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
NSRX vs SSY Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas SSY's P/E ratio is -2.86. In terms of profitability, NSRX's ROE is -1.59%, compared to SSY's ROE of -0.09%. Regarding short-term risk, NSRX is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
NSRX vs SCNX Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, SCNX has a market cap of 5.3M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while SCNX trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas SCNX's P/E ratio is -1.54. In terms of profitability, NSRX's ROE is -1.59%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, NSRX is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check SCNX's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
NSRX vs BGMS Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, BGMS has a market cap of 5.1M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while BGMS trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas BGMS's P/E ratio is -0.26. In terms of profitability, NSRX's ROE is -1.59%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, NSRX is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check BGMS's competition here
POMDOCTOR Ltd (NASDAQ: POM)
NSRX vs POM Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, POM has a market cap of 4.7M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while POM trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas POM's P/E ratio is -0.12. In terms of profitability, NSRX's ROE is -1.59%, compared to POM's ROE of +0.16%. Regarding short-term risk, NSRX is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check POM's competition here
Eocene Ltd. (NASDAQ: EOCN)
NSRX vs EOCN Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, EOCN has a market cap of 3.3M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while EOCN trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas EOCN's P/E ratio is -0.23. In terms of profitability, NSRX's ROE is -1.59%, compared to EOCN's ROE of N/A. Regarding short-term risk, NSRX is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check EOCN's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
NSRX vs BFRIW Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, BFRIW has a market cap of 3.2M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while BFRIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas BFRIW's P/E ratio is -0.01. In terms of profitability, NSRX's ROE is -1.59%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, NSRX is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check BFRIW's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
NSRX vs MDVL Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas MDVL's P/E ratio is -0.05. In terms of profitability, NSRX's ROE is -1.59%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, NSRX is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check MDVL's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
NSRX vs PAVS Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, PAVS has a market cap of 2.9M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while PAVS trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas PAVS's P/E ratio is -0.04. In terms of profitability, NSRX's ROE is -1.59%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, NSRX is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check PAVS's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
NSRX vs ATNFW Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas ATNFW's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, NSRX is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
NSRX vs BGMSP Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, NSRX's ROE is -1.59%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, NSRX is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
NSRX vs AZNH Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas AZNH's P/E ratio is 38.35. In terms of profitability, NSRX's ROE is -1.59%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, NSRX is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
NSRX vs LFLYW Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, NSRX's ROE is -1.59%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, NSRX is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
NSRX vs PRPH Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, PRPH has a market cap of 119.1K. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas PRPH's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, NSRX is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
NSRX vs CPD Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, CPD has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas CPD's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to CPD's ROE of N/A. Regarding short-term risk, NSRX is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
NSRX vs SHPG Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas SHPG's P/E ratio is 11.35. In terms of profitability, NSRX's ROE is -1.59%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, NSRX is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check SHPG's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
NSRX vs IPXL Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas IPXL's P/E ratio is -10.11. In terms of profitability, NSRX's ROE is -1.59%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, NSRX is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check IPXL's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
NSRX vs OREX Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, OREX has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas OREX's P/E ratio is -0.14. In terms of profitability, NSRX's ROE is -1.59%, compared to OREX's ROE of -0.54%. Regarding short-term risk, NSRX is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
NSRX vs POZN Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, POZN has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas POZN's P/E ratio is N/A. In terms of profitability, NSRX's ROE is -1.59%, compared to POZN's ROE of +0.61%. Regarding short-term risk, NSRX is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for NSRX.Check POZN's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
NSRX vs ESRX Comparison October 2026
Nasus Pharma Ltd. (AMEX: NSRX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 27.8M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, NSRX is priced at $3.23 on the AMEX, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -4.49, whereas ESRX's P/E ratio is 10.69. In terms of profitability, NSRX's ROE is -1.59%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, NSRX is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for NSRX.Check ESRX's competition here